Establishment Labs reported a strong Q2 2026 with 31.7% revenue growth and gross margins expanding to 70.6%, driven mainly by U.S. sales which accounted for 89% of growth. The company's FDA-approved Preservé product offers over twice the revenue per breast augmentation procedure compared to traditional implants, positioning it for higher-margin growth. However, the long-term success depends on repeat use and maintaining strong economics. Investors should watch for risks related to Preservé adoption, safety outcomes, and cash flow conversion, especially given the current valuation at 8.91x forward EV/sales.
Exodus Movement, a self-custodial finance and payments platform, will release its third quarter 2026 financial results after market close on November 9, 2026. The company will host a webcast at 5:00 PM ET the same day to discuss the results. Founded ...
Onco360, a leading independent specialty pharmacy, has been selected by AstraZeneca as a national pharmacy partner for Zegfrovy (sunvozertinib), a treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Zegfrovy has s...
S4A IT Solutions has been accepted into the SAP PartnerEdge program, marking a key milestone in its growth. This partnership enhances S4A's ability to help organizations maximize their SAP investments, especially in areas like asset management and su...
Public companies are facing new challenges for the 2027 proxy season due to changes in SEC policies, evolving shareholder activism strategies, and shifts in institutional investor voting. A virtual roundtable on October 28 will gather experts to disc...
Gogo Inc., a leading provider of in-flight broadband connectivity, announced it will report its third quarter 2026 financial results on November 6, 2026, before the market opens. The company will hold a conference call with financial analysts the sam...
